Peiying Li1, Leilei Mao, Guoqing Zhou, Rehana K Leak, Bao-Liang Sun, Jun Chen, Xiaoming Hu. 1. From the Center of Cerebrovascular Disease Research, University of Pittsburgh School of Medicine, Pittsburgh, PA (P.L., L.M., J.C., X.H.); Anesthesiology Department of Huashan Hospital, State Key Laboratory of Medical Neurobiology and Institute of Brain Sciences, Fudan University, Shanghai, China (P.L., L.M., J.C., X.H.); Department of Neurology and Key Laboratory of Cerebral Microcirculation, University of Shandong, Taian, Shandong, China (G.Z., B.-L.S.); Affiliated Hospital of Taishan Medical College, Taian, Shandong, China (G.Z., B.-L.S.); Division of Pharmaceutical Sciences, Mylan School of Pharmacy, Duquesne University, Pittsburgh, PA (R.K.L.); and Geriatric Research, Educational and Clinical Center, Veterans Affairs Pittsburgh Health Care System, Pittsburgh, PA (J.C., X.H.).
Abstract
BACKGROUND AND PURPOSE: Cerebral ischemia has been shown to result in peripheral inflammatory responses followed by long-lasting immunosuppression. Our recent study demonstrated that intravenous delivery of regulatory T cells (Tregs) markedly protected against transient cerebral ischemia by suppressing neutrophil-derived matrix metallopeptidase 9 production in the periphery. However, the effect of Tregs on systemic inflammatory responses and immune status has not been fully characterized. METHODS: Cerebral ischemia was induced by middle cerebral artery occlusion for 60 minutes in mice or 120 minutes in rats. Tregs were isolated from donor animals by CD4 and CD25 double selection and transferred intravenously to ischemic recipients at 2 hours after middle cerebral artery occlusion. Animals were euthanized on different days after reperfusion. The effects of Tregs on systemic inflammation and immune status were evaluated using flow cytometry, ELISAs, and immunohistochemistry. RESULTS: Systemic administration of purified Tregs raises functional Tregs in the blood and peripheral organs, including spleen and lymph nodes. These exogenous Tregs remain in the blood and peripheral organs for ≥12 days. Functionally, Treg adoptive transfer markedly inhibits middle cerebral artery occlusion-induced elevation of inflammatory cytokines (interleukin-6 and tumor necrosis factor α) in the blood. Furthermore, Treg treatment corrects long-term lymphopenia and improves cellular immune functions after ischemic brain injury. As a result, Treg-treated animals exhibit decreased bacterial loads in the blood during recovery from cerebral ischemic attack. CONCLUSIONS: Treg treatment did not exacerbate poststroke immunosuppression. On the contrary, Treg-treated animals displayed improved immune status after focal cerebral ischemia.
BACKGROUND AND PURPOSE:Cerebral ischemia has been shown to result in peripheral inflammatory responses followed by long-lasting immunosuppression. Our recent study demonstrated that intravenous delivery of regulatory T cells (Tregs) markedly protected against transient cerebral ischemia by suppressing neutrophil-derived matrix metallopeptidase 9 production in the periphery. However, the effect of Tregs on systemic inflammatory responses and immune status has not been fully characterized. METHODS:Cerebral ischemia was induced by middle cerebral artery occlusion for 60 minutes in mice or 120 minutes in rats. Tregs were isolated from donor animals by CD4 and CD25 double selection and transferred intravenously to ischemic recipients at 2 hours after middle cerebral artery occlusion. Animals were euthanized on different days after reperfusion. The effects of Tregs on systemic inflammation and immune status were evaluated using flow cytometry, ELISAs, and immunohistochemistry. RESULTS: Systemic administration of purified Tregs raises functional Tregs in the blood and peripheral organs, including spleen and lymph nodes. These exogenous Tregs remain in the blood and peripheral organs for ≥12 days. Functionally, Treg adoptive transfer markedly inhibits middle cerebral artery occlusion-induced elevation of inflammatory cytokines (interleukin-6 and tumor necrosis factor α) in the blood. Furthermore, Treg treatment corrects long-term lymphopenia and improves cellular immune functions after ischemic brain injury. As a result, Treg-treated animals exhibit decreased bacterial loads in the blood during recovery from cerebral ischemic attack. CONCLUSIONS:Treg treatment did not exacerbate poststroke immunosuppression. On the contrary, Treg-treated animals displayed improved immune status after focal cerebral ischemia.
Authors: Christian Meisel; Jan M Schwab; Konstantin Prass; Andreas Meisel; Ulrich Dirnagl Journal: Nat Rev Neurosci Date: 2005-10 Impact factor: 34.870
Authors: Halina Offner; Sandhya Subramanian; Susan M Parker; Michael E Afentoulis; Arthur A Vandenbark; Patricia D Hurn Journal: J Cereb Blood Flow Metab Date: 2006-05 Impact factor: 6.200
Authors: Mar Castellanos; José Castillo; María M García; Rogelio Leira; Joaquín Serena; Angel Chamorro; Antoni Dávalos Journal: Stroke Date: 2002-04 Impact factor: 7.914
Authors: Jun Yan; Judith M Greer; Kellie Etherington; Greg P Cadigan; Helen Cavanagh; Robert D Henderson; John D O'Sullivan; Jeyaraj D Pandian; Stephen J Read; Pamela A McCombe Journal: J Neuroimmunol Date: 2008-12-05 Impact factor: 3.478
Authors: Arthur Liesz; Elisabeth Suri-Payer; Claudia Veltkamp; Henrike Doerr; Clemens Sommer; Serge Rivest; Thomas Giese; Roland Veltkamp Journal: Nat Med Date: 2009-01-25 Impact factor: 53.440
Authors: Konstantin Prass; Christian Meisel; Conny Höflich; Johann Braun; Elke Halle; Tilo Wolf; Karsten Ruscher; Ilya V Victorov; Josef Priller; Ulrich Dirnagl; Hans-Dieter Volk; Andreas Meisel Journal: J Exp Med Date: 2003-08-25 Impact factor: 14.307
Authors: R Anne Stetler; Yanqin Gao; Rehana K Leak; Zhongfang Weng; Yejie Shi; Lili Zhang; Hongjian Pu; Feng Zhang; Xiaoming Hu; Sulaiman Hassan; Carolyn Ferguson; Gregg E Homanics; Guodong Cao; Michael V L Bennett; Jun Chen Journal: Proc Natl Acad Sci U S A Date: 2016-06-06 Impact factor: 11.205